Celltrion Healthcare Secures Consecutive Cancer Drug Orders in Brazil

[Asia Economy Reporter Cho Hyun-ui] Celltrion Healthcare has consecutively succeeded in securing orders for the anticancer biosimilars 'Herzuma' (generic name: trastuzumab) and 'Truxima' (rituximab) in Brazil.

On the 13th, Celltrion Healthcare stated, "Since the beginning of this month, we have been rapidly expanding our market in Brazil, the largest market in Latin America."

Brazil is a key country accounting for more than half of the Latin American biopharmaceutical market. Recently, the Brazilian government has been actively considering the introduction of biosimilars to alleviate the financial burden on healthcare caused by the spread of COVID-19.

As a result, Herzuma won the federal government tender, beating competitors. Celltrion Healthcare will supply Herzuma to the public market, which accounts for about 40% of the Brazilian trastuzumab market, for the next year.

Truxima also succeeded in winning the S?o Paulo tender last week. It is expanding its market by securing contracts in tenders from six state governments this year.

Celltrion Healthcare plans to expand local personnel and continue aggressive marketing activities targeting key stakeholders to continuously increase prescriptions of Herzuma and Truxima.

A Celltrion Healthcare official said, "We are leading the biosimilar market by successfully winning biosimilar tenders recently in Latin America, Asia, and other regions. We will do our best to maintain steady growth based on this momentum."

This content was produced with the assistance of AI translation services.